All In Biotech

Drug Trial Radar · NCT07270848

Dronedarone Rhythm Intervention for Early Atrial Fibrillation

A Multicenter Prospective Study on the Efficacy, Safety, and Quality of Life Improvements of Dronedarone for Early Rhythm Control in Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,898 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,898

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Inha University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare two commonly used types of medicine for treating atrial fibrillation (also called AF), a condition that causes an irregular heart rhythm. This study is for adults who have been diagnosed with AF within the past year. Researchers want to find out which medicine is more effective, safer, and provides a better quality of life for patients needing to control their heart rhythm. Participants who agree to join the study will be randomly assigned (like flipping a coin) to one of two groups: Group 1: Will receive the medicine Dronedarone. Group 2: Will receive a standard medicine from the 'Class Ic' group (such as flecainide or propafenone). The study will follow participants for at least 12 months. Researchers will compare how well each medicine works to prevent AF from coming back. They will also carefully track any side effects and changes in participants' quality of life during the study.

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • DronedaroneDrug

    Dronedarone 400 mg administered orally twice daily.

  • flecainideDrug

    Administered orally according to standard clinical practice.

  • propafenoneDrug

    Administered orally according to standard clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy : Recurrence of Atrial FibrillationTime frame: From randomization up to 12 months
  2. Safety : Rate of Drug Discontinuation Due to Adverse EventsTime frame: Up to 12 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Korea University Ansan Hospital

    Ansan, South Korea

  • Soonchunhyang University Bucheon Hospital

    Bucheon-si, South Korea

  • Kosin University Gospel Hospital

    Busan, South Korea

  • Soonchunhyang University Cheonan Hospital

    Cheonan, South Korea

  • Inje University Ilsan Paik Hospital

    Goyang, South Korea

  • NHIS Ilsan Hospital

    Goyang-si, South Korea

  • Myongji Hospital

    Goyang-si, South Korea

  • Hanyang University Guri Hospital

    Guri-si, South Korea

  • Jeju National University Hospital

    Jeju City, South Korea

  • Sejong Chungnam National University Hospital

    Sejong, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Ewha Womans University Seoul Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, South Korea

  • Inha University Hospital

    Incheon, Incheon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.